BR112012017485A2 - derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído - Google Patents

derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído

Info

Publication number
BR112012017485A2
BR112012017485A2 BR112012017485A BR112012017485A BR112012017485A2 BR 112012017485 A2 BR112012017485 A2 BR 112012017485A2 BR 112012017485 A BR112012017485 A BR 112012017485A BR 112012017485 A BR112012017485 A BR 112012017485A BR 112012017485 A2 BR112012017485 A2 BR 112012017485A2
Authority
BR
Brazil
Prior art keywords
oxazolpyrimidine
substituted
ring
carboxylic acid
acid derivatives
Prior art date
Application number
BR112012017485A
Other languages
English (en)
Inventor
Andreas Gille
Axel Dietrich
Dieter Kadereit
Katrin Hiss
Matthias Schaefer
Stephanie Hachtel
Thomas Huebschle
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012017485A2 publication Critical patent/BR112012017485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de ácido carboxílico tendo um anel de oxazolpiridina 2.5.7-substituído a presente invenção refere-se aos compostos de oxazolpirimidina de fórmula (l), em que a,r^ 1^,r^ 3^,r^ 4^ e x são definidos como declarado nas reivindicações. os compostos de fórmula l são apropriados, por exemplo , para cura de ferimento.
BR112012017485A 2010-01-13 2011-01-12 derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído BR112012017485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305036 2010-01-13
PCT/EP2011/050298 WO2011086077A1 (de) 2010-01-13 2011-01-12 Carbonsäurederivate mit einem 2,5,7-substituierten oxazolopyrimidinring

Publications (1)

Publication Number Publication Date
BR112012017485A2 true BR112012017485A2 (pt) 2016-04-19

Family

ID=42111309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017485A BR112012017485A2 (pt) 2010-01-13 2011-01-12 derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído

Country Status (20)

Country Link
US (1) US8748436B2 (pt)
EP (1) EP2523958B1 (pt)
JP (1) JP5844277B2 (pt)
KR (1) KR101759117B1 (pt)
CN (1) CN103097392B (pt)
AR (1) AR079981A1 (pt)
AU (1) AU2011206613B2 (pt)
BR (1) BR112012017485A2 (pt)
CA (1) CA2799474C (pt)
DK (1) DK2523958T3 (pt)
ES (1) ES2453956T3 (pt)
IL (1) IL220706A (pt)
MX (1) MX2012007870A (pt)
MY (1) MY156960A (pt)
PT (1) PT2523958E (pt)
RU (1) RU2560876C2 (pt)
SG (1) SG182477A1 (pt)
TW (1) TWI478929B (pt)
UY (1) UY33177A (pt)
WO (1) WO2011086077A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33176A (es) 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
BR112012017447B1 (pt) * 2010-01-14 2019-10-29 Sanofi Sa derivados de ácidos carboxílicos heterocíclicos tendo um anel oxazolopirimidina 2,5-substituído, processo para a preparação dos mesmos, e composição farmacêutica
PH12012501265A1 (en) * 2010-01-14 2016-07-27 Sanofi Sa Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
CA2784565C (en) 2010-01-14 2018-03-13 Sanofi 2,5-substituted oxazolopyrimidine derivatives
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
JP6294872B2 (ja) 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
JP2006524672A (ja) 2003-04-25 2006-11-02 ユニバーシティー・カッレッジ・カーディフ・コンサルタンツ・リミテッド ウイルス感染の治療において使用するための複素環式化合物
AU2004251146A1 (en) * 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CN1787817B (zh) * 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
AU2006317689B2 (en) * 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
JP5191497B2 (ja) * 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド Ｓ１ｐ受容体調節化合物およびその使用
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
KR20110042286A (ko) 2008-07-15 2011-04-26 사노피-아벤티스 Ｅｄｇ－１ 수용체 작용제로서의 옥사졸로피리미딘
BR112012017447B1 (pt) 2010-01-14 2019-10-29 Sanofi Sa derivados de ácidos carboxílicos heterocíclicos tendo um anel oxazolopirimidina 2,5-substituído, processo para a preparação dos mesmos, e composição farmacêutica
PH12012501265A1 (en) 2010-01-14 2016-07-27 Sanofi Sa Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
CA2784565C (en) 2010-01-14 2018-03-13 Sanofi 2,5-substituted oxazolopyrimidine derivatives

Also Published As

Publication number Publication date
IL220706A0 (en) 2012-08-30
AU2011206613B2 (en) 2015-04-02
HK1180314A1 (en) 2013-10-18
US20130079357A1 (en) 2013-03-28
TW201136940A (en) 2011-11-01
SG182477A1 (en) 2012-08-30
PT2523958E (pt) 2014-03-27
TWI478929B (zh) 2015-04-01
KR101759117B1 (ko) 2017-07-18
WO2011086077A1 (de) 2011-07-21
CN103097392B (zh) 2015-05-13
UY33177A (es) 2011-08-31
CN103097392A (zh) 2013-05-08
RU2560876C2 (ru) 2015-08-20
IL220706A (en) 2015-06-30
CA2799474A1 (en) 2011-07-21
MX2012007870A (es) 2012-07-25
RU2012134378A (ru) 2014-02-20
AR079981A1 (es) 2012-03-07
JP2013517239A (ja) 2013-05-16
KR20120115397A (ko) 2012-10-17
ES2453956T3 (es) 2014-04-09
EP2523958A1 (de) 2012-11-21
JP5844277B2 (ja) 2016-01-13
AU2011206613A1 (en) 2012-08-02
US8748436B2 (en) 2014-06-10
EP2523958B1 (de) 2013-12-25
MY156960A (en) 2016-04-15
CA2799474C (en) 2018-02-20
DK2523958T3 (da) 2014-03-31

Similar Documents

Publication Publication Date Title
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
BR112012007085B8 (pt) processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
CR20120011A (es) Inhibidores de bace
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
BR112015018504A2 (pt) moduladores de flap
BR112014018756A8 (pt) Processo para preparo de etil éster de ácido n-(4-ciclo-hexil-3-trifluorometil-benziloxi)-acetimídico
BR112012030473A2 (pt) pesticidas baseados em derivados pirrolidina espiroheterocíclicos
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
CO6660462A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
MX2012007835A (es) Derivados de oxazolopirimidina sustituida en 2, 5,7.
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
BR112012017447A2 (pt) derivados de ácidos carboxílicos heterocíclicos tendo um anel oxazolopirimidina 2,5-substituído
UY33179A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
BR112012017240A2 (pt) derivados do ácido heterocíclico carboxílico tendo o anel de 2,5,7-oxazolopirimidina susbtituído
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
BR112016001539A8 (pt) formulações em pó aperfeiçoadas de ácidos orgânicos ou ésteres tendo um sistema de anel aromático

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.